Ropinirole hydrochloride - Parkinson's disease
You are here : Home > Formulary Search > Ropinirole hydrochloride - Parkinson's disease
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Blue
Formulations :
- Tablets
Formulary Status :
Restrictions / Comments :
Documentation
Guidelines (National)
PAD Profile
ChemicalSubstance :
Ropinirole hydrochloride
Indication :
Parkinson's disease
Group Name :
Keywords :
dopamine agonists, non-ergot-derived dopamine receptor agonists, PD, nocturnal akinesia
Brand Names Include :
Adartrel, Aimpart, Ipinnia, Ralnea, Raponer, Repinex, Requip, Ropilynz, Ropiqual
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2
Other Indications
Below are listed other indications that Ropinirole hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Parkinson's disease.
- Amantadine hydrochloride
- Apomorphine hydrochloride
- Bromocriptine
- Cabergoline
- Clonazepam
- Co-beneldopa
- Co-careldopa
- Entacapone
- Foslevodopa with foscarbidopa
- Levodopa with carbidopa and entacapone
- Melatonin
- Opicapone
- Orphenadrine hydrochloride
- Pergolide mesilate
- Pramipexole
- Procyclidine hydrochloride
- Rasagiline mesilate
- Rotigotine
- Safinamide
- Selegiline hydrochloride
- Tolcapone
- Trihexyphenidyl hydrochloride
Committee Recommendations (1)
- Non-ergot derived Dopamine agonists (or levodopa or monoamine oxidase B inhibitors) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
- Non-ergot derived Dopamine agonists are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy
- Non-ergot derived Dopamine agonists may be considered in the treatment of nocturnal akinesia in Parkinson's disease.
Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.